Key Investor Signals
€535,000 in financing and public support behind the spin-out
Constellate secured €150,000 in convertible financing; earlier work received a €200,000 Biotech Booster grant to TU Delft and a €185,000 Faculty of Impact fellowship to Carlos de Lannoy.
Operational platform now open for biopharma and CDMO pilots
Constellate says its TU Delft setup is operational, with titre and glycosylation probes validated and pilot projects open on biopharma and CDMO samples.
Core method demonstrated in Nature Nanotechnology
The single-molecule protein-fingerprinting approach underpinning the platform was demonstrated in a 2024 Nature Nanotechnology paper co-authored by CEO Carlos de Lannoy.
Other Positive Signals
- Received TTT MedTech funding for customer discovery and early hardware development.
- Named one of 10 winners in the 2026 Academic Startup Competition.
- Selected for LifeSciences@Work's Venture Challenge Fall 2025 programme.
Team
Carlos de Lannoy
Co-founder and CEO
- Completed a PhD at Wageningen on single-molecule protein sequencing, then continued the work as a TU Delft postdoctoral researcher.
- Co-authored the 2024 Nature Nanotechnology paper demonstrating full-length single-molecule protein fingerprinting.
- Selected for NWO's 2024 Faculty of Impact fellowship, with €185,000 supporting a full-time commercialisation track.
Dennis de Beeld
Co-founder and CBO
- Co-founded ImmunoWars, a medical-education game that sold 5,000+ copies across more than 30 countries.
- Led ImmunoWars fundraising, incorporation and expansion into education partnerships with hospitals and universities.
- Studied antibody glycosylation at Leiden University Medical Center, giving him direct domain expertise relevant to Constellate.
Arian Khoshchin
Co-founder, Corporate & Commercial Development
- Brings roughly ten years of biotech business-development experience across RNA therapeutics, drug delivery and genomics services.
- Served as Director of Business Development at 20Med Therapeutics after two years as its Business Development Manager.
- Worked at ProQR Therapeutics before leading next-generation sequencing services for biopharma customers at GenomeScan.
Product
RAYmAb is Constellate's single-molecule platform for early antibody cell-line development. It captures individual antibodies from crude supernatant and reads their interactions with fluorescent affinity probes, aiming to measure multiple production and quality attributes from the same small sample.
Measures directly from crude supernatant
RAYmAb captures antibodies directly from crude culture supernatant, avoiding purification before analysis and allowing quality measurements from very small early-stage samples.
Targets four quality attributes in one run
The platform is designed to measure titre, glycosylation, aggregation and charge variants from one sample, replacing separate quality assays across multiple instruments.
Pilot analysis service
Biopharma and CDMO teams can send samples for pilot analysis and receive a cell-line ranking report with titre and glycosylation data within two business days.
Market Overview
Before antibody manufacturing begins, developers select one production cell line from thousands of candidates. The choice affects both yield and product quality, but conventional quality testing usually needs purified material after weeks of cell growth. Early ranking therefore leans heavily on titre, while quality issues may surface only after substantial development work.
Cell-line development is an established biopharma workflow, supported by specialist CDMOs, analytical instruments and outsourced services. The global market is estimated at $1.46B in 2025, while 1,516 antibody candidates were in clinical development as of August 2025, sustaining demand for faster, earlier quality analytics.
Estimated global value of monoclonal antibody medicines in 2025.
Thermo Fisher cites 24–36 weeks for established stable cell-line development workflows.
Estimated global spending on cell-line development services and technologies in 2025.
Antibody drug candidates reported in clinical development worldwide as of August 2025.
Comparable Outcomes
Solentim
Solentim built imaging and single-cell cloning instruments used to isolate, verify and characterise high-value production clones during cell-line development. Advanced Instruments acquired Solentim in 2021 for approximately $240 million.
Olink Proteomics
Olink built a high-throughput proteomics platform for measuring large protein panels from small biological samples, creating a scalable research and biomarker-discovery workflow. Olink listed on Nasdaq in 2021 and was acquired by Thermo Fisher Scientific in 2024 for approximately $3.1 billion.
Interested in More Startups Like Constellate Proteomics?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.